“Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation”-Reference-Cited by-同舟云学术

“Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation”

Published:2020-10-16 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Cuvelier Geoff D. E.,Li Amanda,Drissler Sibyl,Kariminia Amina,Abdossamadi Sayeh,Rozmus Jacob,Chanoine Jean-Pierre,Ng Bernard,Mostafavi Sara,Brinkman Ryan R.,Schultz Kirk R.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference49 articles.

1. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis;Qayed;Biol Blood Marrow Transplant,2018

2. Elevated Numbers of Immature/Transitional CD21- B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients With Active Chronic Graft-Versus-Host Disease;Greinix;Biol Blood Marrow Transplant,2008

3. CD56bright NK regulatory cells in filgrastim primed donor blood or marrow products regulate chronic GvHD: CBMTG randomized 0601 study results;Kariminia;Haematologica,2017

4. Heterogeneity of chronic graft-versus-host disease biomarkers: the only consistent association is with CXCL10 and CXCR3+ NK cells;Kariminia;Blood,2016

5. Biomarker Panel for Chronic Graft-Versus-Host Disease;Yu;J Clin Oncol,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus;Transplantation Proceedings;2024-09

2. Associations between acute and chronic graft-versus-host disease;Blood Advances;2024-08-14

3. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development;Current Oncology;2024-03-08

4. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts;Transplantation and Cellular Therapy;2023-12

5. Treatment of steroid-refractory graft versus host disease in children;Frontiers in Transplantation;2023-09-15